Suggested remit: To appraise the clinical and cost effectiveness of glofitamab with gemcitabine and oxaliplatin within its marketing authorisation for treating relapsed or refractory diffuse large B-cell lymphoma.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6202

Provisional Schedule

Committee meeting 08 July 2025
Expected publication 17 September 2025

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors Roche Products (glofitamab)
Others Department of Health and Social Care
  NHS England
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency for Equality
  Blood Cancer UK
  Cancer Black Care
  Cancer Equality
  Cancer52
  DKMS
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Kevin Karawa Leukaemia Trust
  Leukaemia Cancer Society
  Leukaemia Care
  Leukaemia UK
  Lymphoma Action
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  WMUK
Professional groups Association of Cancer Physicians
  British Geriatrics Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society for Haematology
  British Society of Interventional Radiology
  British Transplantation Society
  Cancer Research UK
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Cutaneous Lymphoma Group
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies AbbVie (epcoritamab)
  Accord Healthcare (bendamustine, etoposide, gemcitabine, prednisolone, oxaliplatin)
  Actavis (bendamustine, etoposide, gemcitabine, prednisolone)
  Advanz Pharma (prednisolone)
  Aspen (chlorambucil)
  Baxter Healthcare (cyclophosphamide, ifosfamide)
  Bristol-Myers Squibb Pharmaceuticals (etoposide)
  Consilient Health (dexamethasone)
  Dr Reddy’s Laboratories UK (bendamustine)
  Eli Lilly and Company (gemcitabine)
  Hospira UK (gemcitabine, oxaliplatin)
  Kite, a Gilead company (axicabtagene ciloleucel)
  Medac UK (bendamustine, etoposide, lomustine, oxaliplatin)
  Napp Pharmaceuticals (bendamustine, rituximab)
  Pfizer (gemcitabine, vincristine)
  Ranbaxy (UK), a Sun Pharmaceutical Company (gemcitabine)
  Roche (glofitamab, polatuzumab vedotin, rituximab)
  Sandoz (cyclophosphamide, rituximab)
  Seacross pharmaceuticals (bendamustine)
  Swedish Orphan Biovitrum (loncastuximab tesirine)
  Teva Nederland B.V. (bleomycin)
  Zentiva (bendamustine, prednisolone)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health – Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematology Group
  Cochrane UK
  Genomics England
  Institute of Cancer Research
  Leukaemia Busters
  Leukaemia UK
  Lymphoma Research Trust
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
25 November 2024 Invitation to participate
26 July 2024 Please note that following on from information received from the company this appraisal has been rescheduled to align with latest regulatory expectations and the appraisal is now anticipated to begin in late November 2024.
19 March 2024 - 18 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6202
19 March 2024 In progress. Scoping commenced.
08 February 2024 Please note that following on from information received from the company, the timelines for this appraisal have now been revised and the appraisal is now anticipated to begin in late July 2024.
16 October 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-June 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
25 October 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual